Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 7/20 | 0.75 |
| ▸ | AKR1C1 | Q04828 | 5/20 | 0.75 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3040564 | 1.00 | AKR1C3 (0.75) | AKR1C3AKR1C1AKR1C2ALDH1A1HTT | |
| SCHEMBL30493211 | 0.87 | ALDH1A1 (0.83) | AKR1C3AKR1C1AKR1C2ALDH1A1HTT | |
| SCHEMBL3053554 | 0.87 | AKR1C3 (0.56) | AKR1C3AKR1C1AKR1C2ALDH1A1HTT | |
| SCHEMBL3053556 | 0.87 | AKR1C3 (0.56) | AKR1C3AKR1C1AKR1C2ALDH1A1HTT | |
| SCHEMBL8078949 | 0.87 | AKR1C3 (0.56) | AKR1C3AKR1C1AKR1C2ALDH1A1HTT | |
| SCHEMBL7842236 | 0.86 | AKR1C3 (1.00) | AKR1C3AKR1C1AKR1C2ALDH1A1HTT | |
| SCHEMBL7842239 | 0.86 | AKR1C3 (1.00) | AKR1C3AKR1C1AKR1C2ALDH1A1HTT | |
| SCHEMBL7847362 | 0.85 | AKR1C3 (0.75) | AKR1C3AKR1C1AKR1C2ALDH1A1HTT | |
| SCHEMBL7844072 | 0.85 | AKR1C3 (1.00) | AKR1C3AKR1C1AKR1C2ALDH1A1HTT | |
| SCHEMBL7832711 | 0.85 | AKR1C3 (0.75) | AKR1C3AKR1C1AKR1C2ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476255-B2 | Histone deacetylase inhibitors | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2013-07-02 | — | — | US | disclosed |
| US-20100222379-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-09-02 | — | — | US | disclosed |
| EP-2205563-A2 | NOVEL HISTONE DEACETYLASE INHIBITORS | Orchid Research Laboratories Limited (IN) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009047615-A2 | NOVEL HISTONE DEACETYLASE INHIBITORS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2009-04-16 | — | — | WO | disclosed |
| EP-0699192-B1 | SUBSTITUTED OXAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2002-07-24 | — | — | EP | disclosed |
| EP-1125932-A2 | Substituted thiazoles for the treatment of inflammation | G.D. SEARLE & CO. (US) | 2001-08-22 | — | — | EP | disclosed |
| US-6090834-A | ANALGESICS; RHEUMATIC DISORDERS; SKIN DISORDERS; GASTROINTESTINAL DISORDERS | G.D. SEARLE & CO. (US) | 2000-07-18 | — | — | US | disclosed |
| EP-0825989-A1 | SUBSTITUTED OXAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1998-03-04 | — | — | EP | disclosed |
| US-5719163-A | ARTHRITIS | G.D. SEARLE & CO. (US) | 1998-02-17 | — | — | US | disclosed |
| US-5668161-A | Substituted thiazoles for the treatment of inflammation | G.D. SEARLE & CO. (US) | 1997-09-16 | — | — | US | disclosed |
| EP-0772606-A1 | SUBSTITUTED THIAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-05-14 | — | — | EP | disclosed |
| WO-1996036617-A1 | SUBSTITUTED OXAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-11-21 | — | — | WO | disclosed |
| EP-0699192-A1 | SUBSTITUTED OXAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-03-06 | — | — | EP | disclosed |
| WO-1996003392-A1 | SUBSTITUTED THIAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-02-08 | — | — | WO | disclosed |
| WO-1994027980-A1 | SUBSTITUTED OXAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1994-12-08 | — | — | WO | disclosed |
| US-4153706-A | ANTIARTHRITIC AGENTS | SMITHKLINE CORPORATION (US) | 1979-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222379-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS | HDAC5, HDAC2, HDAC1 | AKR1C3 520/4885AKR1C1 312/4885AKR1C2 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.